NasdaqGS:AMRXPharmaceuticals
Is It Too Late To Consider Amneal Pharmaceuticals (AMRX) After Its Strong Multi Year Run?
If you are wondering whether Amneal Pharmaceuticals is still priced attractively after its recent run, you are not alone.
The stock last closed at US$13.95, with returns of 1.8% over 7 days, 8.1% over 30 days, 10.2% year to date, 59.8% over 1 year, and a very large 3 year return alongside a 183.5% return over 5 years.
Recent coverage has focused on Amneal Pharmaceuticals as investors reassess the company and its place in the US pharmaceuticals and biotech space. These developments give extra...